Piotr Wysocki: Physicial exercise reduces the risk of recurrence – TNBC and HER2+/HR- breast cancer

Piotr Wysocki recently posted on LinkedIn:

“Soldato D et al. conducted a multicenter prospective cohort analysis comprising 10,359 breast cancer (BC) patients.

The authors assessed exposure to exercise using the Global Physical Activity Questionnaire-16, examining the dose/exposure-response of pretreatment exercise at distant recurrence-free intervals (DRFI). All patients were assessed at diagnosis (before any form of anticancer therapy) and longitudinally during follow-up visits at 1 (corresponding to 3-6 months after completion of primary treatment), 2, 4, and 6 years after diagnosis.

The authors demonstrated that increasing exercise ≥ 5 MET-h/wk was associated with a reduction in DRFI events up to approximately 25 MET-h/wk, but increasing exercise over this threshold did not provide any additional DRFI benefit. Compared with <5 MET-h/wk, the adjusted HR for DRFI was 0.82 (95% CI, 0.61 to 1.00) for ≥ 5 MET-h/wk.

Physical exercise reduced the risk of relapse by:

• 41% in receptor triple-negative BC patients (HR=0.59; 95% CI, 0.38 to 0.92)
• 63% in HER2-positive, non-luminal BC (HR–/HER2+) patients (HR, 0.37; 95% CI, 0.14 to 0.96)
• The benefit of exercise was observed predominantly in the premenopausal patients.”

Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer

Authors: Davide Soldato, Stefan Michiels,  Julie Havas, Antonio Di Meglio, Martina Pagliuca, Maria Alice Franzoi, Barbara Pistilli, Neil M. Iyengar, Paul Cottu, Florence Lerebours, Charles Coutant, Aurélie Bertaut, Oliver Tredan, Laurence Vanlemmens,  Christelle Jouannaud, Iona Hrab, Sibille Everhard, Anne-Laure Martin, Fabrice André, Ines Vaz-Luis and Lee W. Jones

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.

Read other posts by Piotr Wysocki published on OncoDaily.